No abstract

Background: Serum ferritin levels reflecting the body iron stores, is known to be elevated in type 2 Diabetes Mellitus. However its association with diabetic complications including Diabetic nephropathy (DN), and overall glycemic control needs to be validated. Aims and Objectives: The aim of this study was to find the Serum Ferritin level abnormalities in DM patients with nephropathy in comparison with DM patients without nephropathy and to find correlation of Serum Ferritin (SF) levels with levels of Glycated Hemoglobin (HbA1c) in patients with diabetic nephropathy. Materials and Methods: This is a retrospective study, which included eighty five registered patients with Type 2 DM (44 Type II DM without nephropathy cases and 41 cases of Type II DM with nephropathy). SF and HbA1c was estimated in all cases across both the groups and were compared with age and sex matched controls and analysed. Results: Serum Ferritin levels were higher in diabetics with nephropathy compared to diabetics without nephropathy (p<0.0001). SF levels were higher in diabetic groups compared to control group (p <0.001).The correlation between HbA1c and SF was assessed among all cases of DM with nephropathy group using pearson correlation test and it showed a significantly positive correlation (r=0.431) with a SF (mean = 938±148) and HbA1c (mean = 9.2±2.02). Conclusion: Serum ferritin levels positively correlate with HbA1c levels in Type II DM cases with nephropathy, which suggests that serum Ferritin levels can be used as a surrogate marker of glycemic control in Type II DM with nephropathy.

No abstract

: Hyper-coagulability followed by cardiovascular disease is the most common cause of mortality in CKD (chronic kidney disease). Diagnostic usefulness of hypercoagulability marker at various stages of CKD needs to be assessed. : An observational cross-sectional study.: Dept of Biochemistry, Institute of Nephrourology, Bangalore, India from January 2022 to March 2022.Study population consists of CKD patients attending Nephrology outpatient for follow up. They were categorized into 5 stages using eGFR values. Laboratory test including D-Dimer was assayed in all the participants using Abbott Architect ci4100 analyzer. In our study, a peaked and statistically significant (P value = &#60;0.0001) D-Dimer values were observed in stage 4&5 (5.4 ±2.5) in comparison with stage 1, 2 & 3 (0.9±0.2). D- Dimer had strong negative correlationR= - 0.79 with eGFR in stage 5 CKD. D-Dimer assay should be considered as a part of routine investigations in CKD patients especially in developing countries like India, where most of the patients reach hospital only at the later stages of the disease, in order to achieve a better follow-up and management of the disease.